Coronavirus Disease 2019 (COVID-19): Pathogenesis, Immune Responses, and Treatment Options

References (75)

1. 1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
2. 2 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
3. 3 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
4. 4 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
5. 5 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
6. 6 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China [DOI]
7. 7 Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia [DOI]
8. 8 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster [DOI]
9. 9 Pathological findings of COVID-19 associated with acute respiratory distress syndrome [DOI]
10. 10 Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [DOI]
11. 11 SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients [DOI]
12. 12 SARS and MERS: recent insights into emerging coronaviruses [DOI]
13. 13 HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [DOI]
14. 14 Coronavirus Infections—More Than Just the Common Cold [DOI]
15. 15 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [DOI]
16. 16 Viral load of SARS-CoV-2 in clinical samples [DOI]
17. 17 Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic [DOI]
18. 18 Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [DOI]
19. 19 Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome [DOI]
20. 20 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody [DOI]
21. 21 Shared and Distinct Functions of Type I and Type III Interferons [DOI]
22. 22 Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways [DOI]
23. 23 Incubation periods of acute respiratory viral infections: a systematic review [DOI]
24. 24 The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus [DOI]
25. 25 Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection [DOI]
26. 26 Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry [DOI]
27. 27 Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study [DOI]
28. 28 SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon [DOI]
29. 29 Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway [DOI]
30. 30 Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response [DOI]
31. 31 Lopinavir/ritonavir in the treatment of HIV-1 infection: a review [DOI]
32. 32 Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea [DOI]
33. 33 Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus [DOI]
34. 34 Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored [DOI]
35. 35 Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside? [DOI]
36. 36 SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism [DOI]
37. 37 Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-κB Signaling Pathways [DOI]
38. 38 Human-Leukocyte Antigen Class I Cw 1502 and Class II DR 0301 Genotypes Are Associated with Resistance to Severe Acute Respiratory Syndrome (SARS) Infection [DOI]
39. 39 The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis [DOI]
40. 40 Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen [DOI]
41. 41 Macrolide Antibiotics and Survival in Patients With Acute Lung Injury [DOI]
42. 42 Molecular Determinants for Subcellular Localization of the Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame 3b Protein [DOI]
43. 43 Clinical Features of Cytokine Storm Syndrome [DOI]
44. 44 Influence of FcγRIIA and MBL polymorphisms on severe acute respiratory syndrome [DOI]
45. 45 Modulation of the immune response by Middle East respiratory syndrome coronavirus [DOI]
46. 46 Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection [DOI]
47. 47 Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital [DOI]
48. 48 Epidemiology of the four human coronaviruses 229E, HKU1, NL63 and OC43 detected over 30 months in the Singapore military [DOI]
49. 49 Macrolide Antibiotics and Survival in Patients with Acute Lung Injury [DOI]
50. 50 [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. [DOI]
51. 51 La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
52. 52 The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application [DOI]
53. 53 Clinical and immunological features of severe and moderate coronavirus disease 2019 [DOI]
54. 54 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [DOI]
55. 55 Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 [DOI]
56. 56 Molecular immune pathogenesis and diagnosis of COVID-19 [DOI]
57. 57 Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine [DOI]
58. 58 Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study [DOI]
59. 59 Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19 [DOI]
60. 60 Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 [DOI]
61. 61 Clinical characteristics of 82 cases of death from COVID-19 [DOI]
62. 62 Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study [DOI]
63. 63 The potential danger of suboptimal antibody responses in COVID-19 [DOI]
64. 64 COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? [DOI]
65. 65 Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections [DOI]
66. 66 Saliva: potential diagnostic value and transmission of 2019-nCoV [DOI]
67. 67 [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. [DOI]
68. 68 A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? [DOI]
69. 69 COVID-19: the new challenge for rheumatologists [DOI]
70. 70 The Rheumatologist’s Role in COVID-19 [DOI]
71. 71 Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society [DOI]
72. 72 The Involvement of Natural Killer Cells in the Pathogenesis of Severe Acute Respiratory Syndrome [DOI]
73. 73 Delayed Initiation of Remdesivir in a COVID‐19‐Positive Patient [DOI]
74. 74 Functional exhaustion of antiviral lymphocytes in COVID-19 patients [DOI]
75. 75 Viral Kinetics and Antibody Responses in Patients with COVID-19 [DOI]

Cited by 3

Showing 2 of 3 known citations — external sources report more than can currently be individually listed.

Related research

• Pattern of Hearing Impairment in a Tertiary Institution in Ado Ekiti, Nigeria — shares topic coverage
• Weight Gain as Tuberculosis Treatment Regimen Progresses in Patients Receiving Antituberculosis Therapy — shares topic coverage
• TREAT-B has Good Accuracy in Selecting HBV Infected Patients for Treatment in Sudan — shares topic coverage
• Botox Treatment: A Comprehensive Review — shares topic coverage
• Harnessing Artificial Intelligence in Healthcare Analytics: From Diagnosis to Treatment Optimization — shares topic coverage